Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor.

Alzheimer's & dementia (New York, N. Y.)

Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert J, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR.
PMID: 29067308
Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. doi: 10.1016/j.trci.2016.08.001. eCollection 2016 Sep.

OBJECTIVES: Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, JNJ-54861911, were assessed after single and multiple dosing in healthy participants.METHODS: Two randomized, placebo-controlled, double-blind studies were performed using single and...

Cite
Timmers M, Van Broeck B, Ramael S, et al. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement (N Y). 2016;2(3):202-212doi: 10.1016/j.trci.2016.08.001.
Timmers, M., Van Broeck, B., Ramael, S., Slemmon, J., De Waepenaert, K., Russu, A., Bogert, J., Stieltjes, H., Shaw, L. M., Engelborghs, S., Moechars, D., Mercken, M., Liu, E., Sinha, V., Kemp, J., Van Nueten, L., Tritsmans, L., & Streffer, J. R. (2016). Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimer's & dementia (New York, N. Y.), 2(3), 202-212. https://doi.org/10.1016/j.trci.2016.08.001
Timmers, Maarten, et al. "Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor." Alzheimer's & dementia (New York, N. Y.) vol. 2,3 (2016): 202-212. doi: https://doi.org/10.1016/j.trci.2016.08.001
Timmers M, Van Broeck B, Ramael S, Slemmon J, De Waepenaert K, Russu A, Bogert J, Stieltjes H, Shaw LM, Engelborghs S, Moechars D, Mercken M, Liu E, Sinha V, Kemp J, Van Nueten L, Tritsmans L, Streffer JR. Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ-54861911, a potent oral BACE inhibitor. Alzheimers Dement (N Y). 2016 Aug 24;2(3):202-212. doi: 10.1016/j.trci.2016.08.001. eCollection 2016 Sep. PMID: 29067308; PMCID: PMC5651349.
Copy Download .nbib Format: NLM
Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials.

Alzheimer's & dementia (New York, N. Y.)

Xu SX, Samtani MN, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C.
PMID: 29854934
Alzheimers Dement (N Y). 2015 Jul 21;1(2):141-149. doi: 10.1016/j.trci.2015.06.005. eCollection 2015 Sep.

OBJECTIVE: Disability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in METHODS: We evaluated longitudinal changes in DAD scores, baseline factors affecting disease progression, and bapineuzumab effect on disease progression.RESULTS: A beta regression model best described...

Cite
Xu SX, Samtani MN, Russu A, et al. Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimers Dement (N Y). 2015;1(2):141-149doi: 10.1016/j.trci.2015.06.005.
Xu, S. X., Samtani, M. N., Russu, A., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S., Brashear, H. R., Styren, S., & Hu, C. (2015). Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimer's & dementia (New York, N. Y.), 1(2), 141-149. https://doi.org/10.1016/j.trci.2015.06.005
Xu, Steven X, et al. "Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials." Alzheimer's & dementia (New York, N. Y.) vol. 1,2 (2015): 141-149. doi: https://doi.org/10.1016/j.trci.2015.06.005
Xu SX, Samtani MN, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C. Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimers Dement (N Y). 2015 Jul 21;1(2):141-149. doi: 10.1016/j.trci.2015.06.005. eCollection 2015 Sep. PMID: 29854934; PMCID: PMC5975025.
Copy Download .nbib Format: NLM
Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab.

Alzheimer's & dementia (New York, N. Y.)

Samtani MN, Xu SX, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C.
PMID: 29854935
Alzheimers Dement (N Y). 2015 Oct 09;1(3):157-169. doi: 10.1016/j.trci.2015.09.001. eCollection 2015 Nov.

INTRODUCTION: The objective of this study was to estimate longitudinal changes in disease progression (measured by Alzheimer's disease assessment scale-cognitive 11-item [ADAS-cog/11] scale) after bapineuzumab treatment and to identify covariates (demographics or baseline characteristics) contributing to the variability in...

Cite
Samtani MN, Xu SX, Russu A, et al. Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab. Alzheimers Dement (N Y). 2015;1(3):157-169doi: 10.1016/j.trci.2015.09.001.
Samtani, M. N., Xu, S. X., Russu, A., Adedokun, O. J., Lu, M., Ito, K., Corrigan, B., Raje, S., Brashear, H. R., Styren, S., & Hu, C. (2015). Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab. Alzheimer's & dementia (New York, N. Y.), 1(3), 157-169. https://doi.org/10.1016/j.trci.2015.09.001
Samtani, Mahesh N, et al. "Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab." Alzheimer's & dementia (New York, N. Y.) vol. 1,3 (2015): 157-169. doi: https://doi.org/10.1016/j.trci.2015.09.001
Samtani MN, Xu SX, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C. Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab. Alzheimers Dement (N Y). 2015 Oct 09;1(3):157-169. doi: 10.1016/j.trci.2015.09.001. eCollection 2015 Nov. PMID: 29854935; PMCID: PMC5975060.
Copy Download .nbib Format: NLM
Atrial lead perforation early after device implantation: A case series.

HeartRhythm case reports

Grebmer C, Russi I, Kobza R, Berte B.
PMID: 33665111
HeartRhythm Case Rep. 2020 Dec 02;7(2):100-105. doi: 10.1016/j.hrcr.2020.11.012. eCollection 2021 Feb.

No abstract available.

Cite
Grebmer C, Russi I, Kobza R, et al. Atrial lead perforation early after device implantation: A case series. HeartRhythm Case Rep. 2020;7(2):100-105doi: 10.1016/j.hrcr.2020.11.012.
Grebmer, C., Russi, I., Kobza, R., & Berte, B. (2021). Atrial lead perforation early after device implantation: A case series. HeartRhythm case reports, 7(2), 100-105. https://doi.org/10.1016/j.hrcr.2020.11.012
Grebmer, Christian, et al. "Atrial lead perforation early after device implantation: A case series." HeartRhythm case reports vol. 7,2 (2021): 100-105. doi: https://doi.org/10.1016/j.hrcr.2020.11.012
Grebmer C, Russi I, Kobza R, Berte B. Atrial lead perforation early after device implantation: A case series. HeartRhythm Case Rep. 2020 Dec 02;7(2):100-105. doi: 10.1016/j.hrcr.2020.11.012. eCollection 2021 Feb. PMID: 33665111; PMCID: PMC7897742.
Copy Download .nbib Format: NLM
A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas.

Frontiers in oncology

Russo I, Di Paolo V, Crocoli A, Mastronuzzi A, Serra A, Di Paolo PL, Di Giannatale A, Miele E, Milano GM.
PMID: 32850366
Front Oncol. 2020 Aug 06;10:1228. doi: 10.3389/fonc.2020.01228. eCollection 2020.

No abstract available.

Cite
Russo I, Di Paolo V, Crocoli A, et al. A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. Front Oncol. 2020;10:1228doi: 10.3389/fonc.2020.01228.
Russo, I., Di Paolo, V., Crocoli, A., Mastronuzzi, A., Serra, A., Di Paolo, P. L., Di Giannatale, A., Miele, E., & Milano, G. M. (2020). A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. Frontiers in oncology, 101228. https://doi.org/10.3389/fonc.2020.01228
Russo, Ida, et al. "A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas." Frontiers in oncology vol. 10 (2020): 1228. doi: https://doi.org/10.3389/fonc.2020.01228
Russo I, Di Paolo V, Crocoli A, Mastronuzzi A, Serra A, Di Paolo PL, Di Giannatale A, Miele E, Milano GM. A Chart Review on the Feasibility and Safety of the Vincristine Irinotecan Pazopanib (VIPaz) Association in Children and Adolescents With Resistant or Relapsed Sarcomas. Front Oncol. 2020 Aug 06;10:1228. doi: 10.3389/fonc.2020.01228. eCollection 2020. PMID: 32850366; PMCID: PMC7425124.
Copy Download .nbib Format: NLM
Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding.

Cancers

Galardi A, Colletti M, Lavarello C, Di Paolo V, Mascio P, Russo I, Cozza R, Romanzo A, Valente P, De Vito R, Pascucci L, Peinado H, Carcaboso AM, Petretto A, Locatelli F, Di Giannatale A.
PMID: 32545553
Cancers (Basel). 2020 Jun 12;12(6). doi: 10.3390/cancers12061555.

Retinoblastoma (RB) is the most common tumor of the eye in early childhood. Although recent advances in conservative treatment have greatly improved the visual outcome, local tumor control remains difficult in the presence of massive vitreous seeding. Traditional biopsy...

Cite
Galardi A, Colletti M, Lavarello C, et al. Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding. Cancers (Basel). 2020;12(6)doi: 10.3390/cancers12061555.
Galardi, A., Colletti, M., Lavarello, C., Di Paolo, V., Mascio, P., Russo, I., Cozza, R., Romanzo, A., Valente, P., De Vito, R., Pascucci, L., Peinado, H., Carcaboso, A. M., Petretto, A., Locatelli, F., & Di Giannatale, A. (2020). Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding. Cancers, 12(6), . https://doi.org/10.3390/cancers12061555
Galardi, Angela, et al. "Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding." Cancers vol. 12,6 (2020). doi: https://doi.org/10.3390/cancers12061555
Galardi A, Colletti M, Lavarello C, Di Paolo V, Mascio P, Russo I, Cozza R, Romanzo A, Valente P, De Vito R, Pascucci L, Peinado H, Carcaboso AM, Petretto A, Locatelli F, Di Giannatale A. Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding. Cancers (Basel). 2020 Jun 12;12(6). doi: 10.3390/cancers12061555. PMID: 32545553; PMCID: PMC7352325.
Copy Download .nbib Format: NLM
Heart Valve Abnormalities in Systemic Sclerosis Patients: A Multicenter Cohort Study and Review of the Literature.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Colaci M, Schinocca C, Bosco YD, Ronsivalle G, Guggino G, de Andres I, Russo AA, Sambataro D, Sambataro G, Malatino L.
PMID: 33252390
J Clin Rheumatol. 2020 Nov 24; doi: 10.1097/RHU.0000000000001638. Epub 2020 Nov 24.

BACKGROUND: Systemic sclerosis (SSc) is a chronic autoimmune disease that is characterized by vasculopathy and fibrosis of the skin and visceral organs. Heart valve diseases are poorly described and generally not considered typical of SSc. We aimed to describe...

Cite
Colaci M, Schinocca C, Bosco YD, et al. Heart Valve Abnormalities in Systemic Sclerosis Patients: A Multicenter Cohort Study and Review of the Literature. J Clin Rheumatol. 2020;doi: 10.1097/RHU.0000000000001638.
Colaci, M., Schinocca, C., Bosco, Y. D., Ronsivalle, G., Guggino, G., de Andres, I., Russo, A. A., Sambataro, D., Sambataro, G., & Malatino, L. (2020). Heart Valve Abnormalities in Systemic Sclerosis Patients: A Multicenter Cohort Study and Review of the Literature. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, . https://doi.org/10.1097/RHU.0000000000001638
Colaci, Michele, et al. "Heart Valve Abnormalities in Systemic Sclerosis Patients: A Multicenter Cohort Study and Review of the Literature." Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases vol. (2020). doi: https://doi.org/10.1097/RHU.0000000000001638
Colaci M, Schinocca C, Bosco YD, Ronsivalle G, Guggino G, de Andres I, Russo AA, Sambataro D, Sambataro G, Malatino L. Heart Valve Abnormalities in Systemic Sclerosis Patients: A Multicenter Cohort Study and Review of the Literature. J Clin Rheumatol. 2020 Nov 24; doi: 10.1097/RHU.0000000000001638. Epub 2020 Nov 24. PMID: 33252390.
Copy Download .nbib Format: NLM
Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?.

Minerva surgery

Costanzo A, Ghidini A, Petrelli F, Turati L, Rampulla V, Varricchio A, Trizzino A, Russo AA, Sgroi G.
PMID: 34047530
Minerva Surg. 2021 May 28; doi: 10.23736/S2724-5691.21.08770-0. Epub 2021 May 28.

BACKGROUND: Optimal time between neoadjuvant radio-chemotherapy period and surgery remains controversial in patients with rectal cancer: an increasing number of studies show results in favour of a long interval.METHODS: We conducted a retrospective analysis of the cases of low-middle...

Cite
Costanzo A, Ghidini A, Petrelli F, et al. Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?. Minerva Surg. 2021;doi: 10.23736/S2724-5691.21.08770-0.
Costanzo, A., Ghidini, A., Petrelli, F., Turati, L., Rampulla, V., Varricchio, A., Trizzino, A., Russo, A. A., & Sgroi, G. (2021). Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?. Minerva surgery, . https://doi.org/10.23736/S2724-5691.21.08770-0
Costanzo, Antonio, et al. "Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?." Minerva surgery vol. (2021). doi: https://doi.org/10.23736/S2724-5691.21.08770-0
Costanzo A, Ghidini A, Petrelli F, Turati L, Rampulla V, Varricchio A, Trizzino A, Russo AA, Sgroi G. Time interval between neoadjuvant radio-chemotherapy and surgery in rectal cancer: is the long interval correct for all patients?. Minerva Surg. 2021 May 28; doi: 10.23736/S2724-5691.21.08770-0. Epub 2021 May 28. PMID: 34047530.
Copy Download .nbib Format: NLM
Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript.

Children (Basel, Switzerland)

Di Ruscio V, Mastronuzzi A, Russo I, Neri M, Stracuzzi A, Giovannoni I, Tropiano ML, De Ioris MA, Milano GM.
PMID: 34203606
Children (Basel). 2021 Jun 15;8(6). doi: 10.3390/children8060505.

Inflammatory myofibroblastic tumor (IMT) is a rare disease that mainly involves the lung and the abdomen with an intermediate clinical course but a recurrence rate between 15-30%. Radical surgery represents the gold standard of treatment, while chemotherapy and radiotherapy...

Cite
Di Ruscio V, Mastronuzzi A, Russo I, et al. Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript. Children (Basel). 2021;8(6)doi: 10.3390/children8060505.
Di Ruscio, V., Mastronuzzi, A., Russo, I., Neri, M., Stracuzzi, A., Giovannoni, I., Tropiano, M. L., De Ioris, M. A., & Milano, G. M. (2021). Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript. Children (Basel, Switzerland), 8(6), . https://doi.org/10.3390/children8060505
Di Ruscio, Valentina, et al. "Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript." Children (Basel, Switzerland) vol. 8,6 (2021). doi: https://doi.org/10.3390/children8060505
Di Ruscio V, Mastronuzzi A, Russo I, Neri M, Stracuzzi A, Giovannoni I, Tropiano ML, De Ioris MA, Milano GM. Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript. Children (Basel). 2021 Jun 15;8(6). doi: 10.3390/children8060505. PMID: 34203606; PMCID: PMC8232338.
Copy Download .nbib Format: NLM
Reply to Huszár: The elastic weight consolidation penalty is empirically valid.

Proceedings of the National Academy of Sciences of the United States of America

Kirkpatrick J, Pascanu R, Rabinowitz N, Veness J, Desjardins G, Rusu AA, Milan K, Quan J, Ramalho T, Grabska-Barwinska A, Hassabis D, Clopath C, Kumaran D, Hadsell R.
PMID: 29463734
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2498. doi: 10.1073/pnas.1800157115. Epub 2018 Feb 20.

No abstract available.

Cite
Kirkpatrick J, Pascanu R, Rabinowitz N, et al. Reply to Huszár: The elastic weight consolidation penalty is empirically valid. Proc Natl Acad Sci U S A. 2018;115(11):E2498doi: 10.1073/pnas.1800157115.
Kirkpatrick, J., Pascanu, R., Rabinowitz, N., Veness, J., Desjardins, G., Rusu, A. A., Milan, K., Quan, J., Ramalho, T., Grabska-Barwinska, A., Hassabis, D., Clopath, C., Kumaran, D., & Hadsell, R. (2018). Reply to Huszár: The elastic weight consolidation penalty is empirically valid. Proceedings of the National Academy of Sciences of the United States of America, 115(11), E2498. https://doi.org/10.1073/pnas.1800157115
Kirkpatrick, James, et al. "Reply to Huszár: The elastic weight consolidation penalty is empirically valid." Proceedings of the National Academy of Sciences of the United States of America vol. 115,11 (2018): E2498. doi: https://doi.org/10.1073/pnas.1800157115
Kirkpatrick J, Pascanu R, Rabinowitz N, Veness J, Desjardins G, Rusu AA, Milan K, Quan J, Ramalho T, Grabska-Barwinska A, Hassabis D, Clopath C, Kumaran D, Hadsell R. Reply to Huszár: The elastic weight consolidation penalty is empirically valid. Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2498. doi: 10.1073/pnas.1800157115. Epub 2018 Feb 20. PMID: 29463734; PMCID: PMC5856563.
Copy Download .nbib Format: NLM
Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells.

Journal of extracellular vesicles

Colletti M, Tomao L, Galardi A, Paolini A, Di Paolo V, De Stefanis C, Mascio P, Nazio F, Petrini S, Castellano A, Russo I, Caruso R, Piga S, De Vito R, Pascucci L, Peinado H, Masotti A, Locatelli F, Di Giannatale A.
PMID: 32922693
J Extracell Vesicles. 2020 Jun 03;9(1):1774144. doi: 10.1080/20013078.2020.1774144.

Bone marrow (BM) is the major target organ for neuroblastoma (NB) metastasis and its involvement is associated with poor outcome. Yet, the mechanism by which NB cells invade BM is largely unknown. Tumour microenvironment represents a key element in...

Cite
Colletti M, Tomao L, Galardi A, et al. Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells. J Extracell Vesicles. 2020;9(1):1774144doi: 10.1080/20013078.2020.1774144.
Colletti, M., Tomao, L., Galardi, A., Paolini, A., Di Paolo, V., De Stefanis, C., Mascio, P., Nazio, F., Petrini, S., Castellano, A., Russo, I., Caruso, R., Piga, S., De Vito, R., Pascucci, L., Peinado, H., Masotti, A., Locatelli, F., & Di Giannatale, A. (2020). Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells. Journal of extracellular vesicles, 9(1), 1774144. https://doi.org/10.1080/20013078.2020.1774144
Colletti, Marta, et al. "Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells." Journal of extracellular vesicles vol. 9,1 (2020): 1774144. doi: https://doi.org/10.1080/20013078.2020.1774144
Colletti M, Tomao L, Galardi A, Paolini A, Di Paolo V, De Stefanis C, Mascio P, Nazio F, Petrini S, Castellano A, Russo I, Caruso R, Piga S, De Vito R, Pascucci L, Peinado H, Masotti A, Locatelli F, Di Giannatale A. Neuroblastoma-secreted exosomes carrying miR-375 promote osteogenic differentiation of bone-marrow mesenchymal stromal cells. J Extracell Vesicles. 2020 Jun 03;9(1):1774144. doi: 10.1080/20013078.2020.1774144. PMID: 32922693; PMCID: PMC7448845.
Copy Download .nbib Format: NLM
Pattern changes in quantitative and qualitative markers of hematopoietic stem cells during acute and chronic exposure to 90Sr isotope in cell culture.

Problemy radiatsiinoi medytsyny ta radiobiolohii

Russu IZ, Rodionova NK, Bilko DI, Bilko NM.
PMID: 26695929
Probl Radiac Med Radiobiol. 2015 Dec;20:533-42.

OBJECTIVE: The objective of our research was investigation of the hematopoietic system of laboratory rats under the influence of acute and chronic internal exposure to 90Sr isotope.MATERIALS AND METHODS: To study the condition of stem cells and their immediate...

Cite
Russu IZ, Rodionova NK, Bilko DI, et al. ZAKONOMIRNOSTI ZMIN KIL'KISNYKh I IaKISNYKh POKAZNYKIV GEMOPOETYChNYKh STOVBUROVYKh KLITYN U KUL'TURI KLITYN V UMOVAKh DIi RADIONUKLIDU STRONTsIIu-90. Pattern changes in quantitative and qualitative markers of hematopoietic stem cells during acute and chronic exposure to 90Sr isotope in cell culture. Probl Radiac Med Radiobiol. 2015;20:533-42
Russu, I. Z., Rodionova, N. K., Bilko, D. I., & Bilko, N. M. (2015). ZAKONOMIRNOSTI ZMIN KIL'KISNYKh I IaKISNYKh POKAZNYKIV GEMOPOETYChNYKh STOVBUROVYKh KLITYN U KUL'TURI KLITYN V UMOVAKh DIi RADIONUKLIDU STRONTsIIu-90. Pattern changes in quantitative and qualitative markers of hematopoietic stem cells during acute and chronic exposure to 90Sr isotope in cell culture. Problemy radiatsiinoi medytsyny ta radiobiolohii, 20533-42.
Russu, I Z, et al. "ZAKONOMIRNOSTI ZMIN KIL'KISNYKh I IaKISNYKh POKAZNYKIV GEMOPOETYChNYKh STOVBUROVYKh KLITYN U KUL'TURI KLITYN V UMOVAKh DIi RADIONUKLIDU STRONTsIIu-90." Pattern changes in quantitative and qualitative markers of hematopoietic stem cells during acute and chronic exposure to 90Sr isotope in cell culture. Problemy radiatsiinoi medytsyny ta radiobiolohii vol. 20 (2015): 533-42.
Russu IZ, Rodionova NK, Bilko DI, Bilko NM. ZAKONOMIRNOSTI ZMIN KIL'KISNYKh I IaKISNYKh POKAZNYKIV GEMOPOETYChNYKh STOVBUROVYKh KLITYN U KUL'TURI KLITYN V UMOVAKh DIi RADIONUKLIDU STRONTsIIu-90. Pattern changes in quantitative and qualitative markers of hematopoietic stem cells during acute and chronic exposure to 90Sr isotope in cell culture. Probl Radiac Med Radiobiol. 2015 Dec;20:533-42. Ukrainian. PMID: 26695929.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries